Capecitabine
- Generic Name
- Capecitabine
- Brand Names
- Ecansya, Xeloda, Capecitabine Medac, Ecansya (previously Capecitabine Krka), Capecitabine Accord, Capecitabine Teva
- Drug Type
- Small Molecule
- Chemical Formula
- C15H22FN3O6
- CAS Number
- 154361-50-9
- Unique Ingredient Identifier
- 6804DJ8Z9U
- Background
Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, that is enzymatically converted to fluorouracil (antimetabolite) in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue.
- Indication
Capecitabine is indicated as treatment for a variety of cancer types. For colorectal cancer, capecitabine is indicated as a single agent or a component of a combination chemotherapy regiment for the adjuvant treatment of stage III colon cancer and treatment unresectable or metastatic colorectal cancer. It can also be used as a part of a combination chemotherapy perioperative treatment of adult locally advanced rectal cancer. For breast cancer, capecitabine is indicated for advanced or metastatic breast cancer as a single agent if an anthracycline- or taxane-containing chemotherapy is not indicated or as a regimen with docetaxel after disease progression on prior anthracycline-containing chemotherapy. For gastric, esophageal, or gastroesophageal junction (GEJ) cancer, capecitabine is indicated as a component of a combination chemotherapy treatment for the treatment of adult unresectable or metastatic gastric, esophageal, or GEJ cancer or adult HER2-overexpressing metastatic gastric or GEJ adenocarcinoma who have not received prior treatment for metastatic disease. Finally, for pancreatic cancer, capecitabine is indicated as adjuvant treatment for adult pancreatic adenocarcinoma as a component of a combination chemotherapy regimen.
- Associated Conditions
- Advanced or Metastatic Breast Cancer, Carcinoma of Gallbladder, Cholangiocarcinoma, Hepatocellular Carcinoma, Locally Advanced Rectal Cancer (LARC), Metastatic Adenocarcinoma of the Gastroesophageal Junction, Metastatic Gastric Cancers, Metastatic Neuroendocrine Tumors, Pancreatic Adenocarcinoma, Pancreatic Cancer, Advanced or Metastatic, Platinum-resistant Epithelial Ovarian Cancer, Refractory Fallopian Tube Carcinoma, Stage III Colon Cancer, Unresectable or Metastatic Colorectal Cancer, Metastatic pancreatic endocrine carcinoma, Refractory peritoneal cancer, Refractory, metastatic Colorectal carcinoma, Unresectable, metastatic Esophageal Cancer, Unresectable, metastatic Gastric Cancer, Unresectable, metastatic Gastroesophageal Junction Cancer
- Associated Therapies
- Chemotherapy
Radiation Therapy and Capecitabine With or Without Oxaliplatin in Treating Patients Who Are Undergoing Surgery for Stage II or Stage III Rectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2005-09-28
- Last Posted Date
- 2021-02-17
- Lead Sponsor
- UNICANCER
- Target Recruit Count
- 598
- Registration Number
- NCT00227747
- Locations
- 🇫🇷
Centre Regional Francois Baclesse, Caen, France
🇫🇷Hopital Drevon, Dijon, France
🇫🇷Polyclinique Bordeaux Nord Aquitaine, Bordeaux, France
A Trial of Thalidomide and Capecitabine in Metastatic Renal Cell Carcinoma
- Conditions
- First Posted Date
- 2005-09-27
- Last Posted Date
- 2009-04-14
- Lead Sponsor
- Stanford University
- Target Recruit Count
- 30
- Registration Number
- NCT00226980
- Locations
- 🇺🇸
Stanford University School of Medicine, Stanford, California, United States
A Phase 1-2 Trial of Cetuximab in Combination With Oxaliplatin, Capecitabine, and Radiation Therapy Followed by Surgery for Locally-advanced Rectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2005-09-27
- Last Posted Date
- 2017-12-08
- Lead Sponsor
- George Albert Fisher
- Target Recruit Count
- 23
- Registration Number
- NCT00226941
- Locations
- 🇺🇸
Stanford University School of Medicine, Stanford, California, United States
Oxaliplatin, Irinotecan, and Capecitabine in Treating Patients With Advanced or Metastatic Colorectal Cancer That Cannot Be Removed By Surgery
- Conditions
- Interventions
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2012-06-05
- Lead Sponsor
- Swiss Group for Clinical Cancer Research
- Target Recruit Count
- 23
- Registration Number
- NCT00217711
- Locations
- 🇨🇭
Hirslanden Klinik Aarau, Lausanne, Switzerland
🇨🇭City Hospital Triemli, Zurich, Switzerland
🇨🇭Kantonsspital Graubuenden, Chur, Switzerland
Capecitabine and Oxaliplatin in Treating Patients With Metastatic Breast Cancer
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2015-12-09
- Lead Sponsor
- Hoosier Cancer Research Network
- Target Recruit Count
- 25
- Registration Number
- NCT00216021
- Locations
- 🇺🇸
Medical & Surgical Specialists, LLC, Galesburg, Illinois, United States
🇺🇸Indiana University Cancer Center, Indianapolis, Indiana, United States
🇺🇸Helen F. Graham Cancer Center, Newark, Delaware, United States
Study of Capecitabine With Irinotecan and Oxaliplatin (Eloxatin) in Advanced Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2013-11-25
- Target Recruit Count
- 24
- Registration Number
- NCT00215982
- Locations
- 🇺🇸
H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States
🇵🇷San Juan Veterans Hospital, Rio Piedras, Puerto Rico
Capecitabine, Oxaliplatin and Trastuzumab in Treating Patients With HER2 Positive Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2011-05-02
- Lead Sponsor
- Hoosier Cancer Research Network
- Target Recruit Count
- 11
- Registration Number
- NCT00216073
- Locations
- 🇺🇸
Medical & Surgical Specialists, LLC, Galesburg, Illinois, United States
🇺🇸Indiana University Cancer Center, Indianapolis, Indiana, United States
🇺🇸Quality Cancer Center (MCGOP), Indianapolis, Indiana, United States
Docetaxel and Capecitabine for First Line Treatment of Metastatic Squamous Cell Carcinoma of the Head & Neck
- Conditions
- Interventions
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2011-05-02
- Lead Sponsor
- Hoosier Cancer Research Network
- Target Recruit Count
- 19
- Registration Number
- NCT00216138
- Locations
- 🇺🇸
Elkhart Clinic, Elkhart, Indiana, United States
🇺🇸Helen F. Graham Cancer Center, Newark, Delaware, United States
🇺🇸Arnett Cancer Care, Lafayette, Indiana, United States
Capecitabine or 5-Fluorouracil in Combination With Irinotecan and Cisplatin in Patients With Solid Tumor Malignancies
- Conditions
- Interventions
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2018-11-02
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 54
- Registration Number
- NCT00215501
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Capecitabine + Irinotecan Followed by Combined Modality Capecitabine and Radiation in Locally Advanced Rectal Cancer
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2016-06-06
- Lead Sponsor
- Gabi Chiorean, MD
- Target Recruit Count
- 22
- Registration Number
- NCT00216086
- Locations
- 🇺🇸
AP&S Clinic, Terre Haute, Indiana, United States
🇺🇸Elkhart Clinic, Elkhart, Indiana, United States
🇺🇸Fort Wayne Oncology & Hematology, Inc, Fort Wayne, Indiana, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.